ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Rating) – Investment analysts at Zacks Research issued their FY2025 earnings per share estimates for ACADIA Pharmaceuticals in a research note issued to investors on Monday, March 13th. Zacks Research analyst K. Saha anticipates that the biopharmaceutical company will earn $0.18 per share for the year. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is ($0.66) per share.
ACAD has been the subject of a number of other research reports. Mizuho increased their price objective on ACADIA Pharmaceuticals from $19.00 to $20.00 in a research note on Tuesday. Morgan Stanley upped their price target on shares of ACADIA Pharmaceuticals from $19.00 to $20.00 and gave the stock an “equal weight” rating in a research note on Tuesday. Canaccord Genuity Group upped their target price on shares of ACADIA Pharmaceuticals from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday. Guggenheim raised their price target on shares of ACADIA Pharmaceuticals from $22.00 to $25.00 in a research report on Tuesday. Finally, Cantor Fitzgerald lifted their target price on ACADIA Pharmaceuticals from $28.00 to $33.00 and gave the stock an “overweight” rating in a report on Tuesday. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $21.44.
ACADIA Pharmaceuticals Stock Performance
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Rating) last issued its earnings results on Monday, February 27th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.01). The firm had revenue of $136.49 million during the quarter, compared to analysts’ expectations of $135.18 million. ACADIA Pharmaceuticals had a negative return on equity of 50.65% and a negative net margin of 41.76%. The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.27) EPS.
Insider Activity at ACADIA Pharmaceuticals
In related news, CEO Stephen Davis sold 3,904 shares of the company’s stock in a transaction dated Monday, January 9th. The stock was sold at an average price of $17.13, for a total transaction of $66,875.52. Following the transaction, the chief executive officer now directly owns 84,633 shares of the company’s stock, valued at approximately $1,449,763.29. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other ACADIA Pharmaceuticals news, CEO Stephen Davis sold 3,904 shares of the business’s stock in a transaction dated Monday, January 9th. The stock was sold at an average price of $17.13, for a total transaction of $66,875.52. Following the sale, the chief executive officer now owns 84,633 shares in the company, valued at approximately $1,449,763.29. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Laura Brege sold 12,500 shares of the business’s stock in a transaction dated Thursday, January 12th. The shares were sold at an average price of $18.25, for a total value of $228,125.00. The disclosure for this sale can be found here. Insiders have sold 23,567 shares of company stock valued at $427,672 in the last ninety days. Corporate insiders own 28.40% of the company’s stock.
Institutional Trading of ACADIA Pharmaceuticals
A number of hedge funds have recently modified their holdings of ACAD. Raymond James Financial Services Advisors Inc. acquired a new position in shares of ACADIA Pharmaceuticals during the first quarter valued at approximately $572,000. HighTower Advisors LLC acquired a new position in ACADIA Pharmaceuticals in the 1st quarter valued at about $1,077,000. MetLife Investment Management LLC increased its position in ACADIA Pharmaceuticals by 54.0% in the 1st quarter. MetLife Investment Management LLC now owns 66,351 shares of the biopharmaceutical company’s stock valued at $1,607,000 after acquiring an additional 23,265 shares during the period. Rhumbline Advisers boosted its holdings in ACADIA Pharmaceuticals by 3.9% in the 1st quarter. Rhumbline Advisers now owns 133,444 shares of the biopharmaceutical company’s stock valued at $3,232,000 after purchasing an additional 5,011 shares in the last quarter. Finally, Canada Pension Plan Investment Board purchased a new stake in ACADIA Pharmaceuticals in the 1st quarter valued at approximately $1,380,000. Hedge funds and other institutional investors own 92.79% of the company’s stock.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals, Inc is a biopharmaceutical company, which focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
- Get a free copy of the StockNews.com research report on ACADIA Pharmaceuticals (ACAD)
- Meta Platforms: Efficiency Gains Momentum, Stock Accelerates
- Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
- SentinelOne: Reversal In-Play For Cybersecurity Stocks
- Is Sportradar Group A Growth Stock To Bet On In 2023?
- Strong Guidance says Boeing is Ready for Takeoff
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.